Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 2/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.30 |
| ▸ | HRAS | P01112 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214936 | 1.00 | POLB (0.35) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL15281797 | 0.88 | POLB (0.47) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL16214939 | 0.88 | POLB (0.47) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL13592887 | 0.86 | MAPT (0.37) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL15281799 | 0.85 | POLB (0.41) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL13592886 | 0.85 | POLB (0.41) | POLBMEN1USP2KMT2AMAPT | |
| SCHEMBL13592077 | 0.83 | LMNA (0.35) | POLBP2RY6P2RY14NT5E | |
| SCHEMBL13523532 | 0.83 | POLB (0.39) | POLBMEN1USP2KMT2AP2RY6 | |
| SCHEMBL13671118 | 0.83 | POLB (0.39) | POLBMEN1USP2KMT2AP2RY6 | |
| SCHEMBL13523800 | 0.83 | POLB (0.39) | POLBMEN1USP2KMT2AP2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | POLB 954/4885MEN1 3666/4885USP2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.